Calamos Advisors
AGN.PRA

Calamos Advisors’s Allergan plc AGN.PRA Stock Holding History

Calamos Advisors’s Portfolio AGN.PRA Stock Details AGN.PRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-157,766
Closed -$92.5M – 641
2017
Q4 		$92.5M Buy
157,766
+459
+0.3% +$296K 0.47% 26
2017
Q3 		$116M Sell
157,307
-23,723
-13% -$19.7M 0.9% 15
2017
Q2 		$157M Sell
181,030
-1,311
-0.7% -$1.1M 1.16% 12
2017
Q1 		$155M Sell
182,341
-1,870
-1% -$1.55M 1.22% 10
2016
Q4 		$140M Sell
184,211
-70,648
-28% -$53.4M 1.12% 11
2016
Q3 		$209M Sell
254,859
-17,797
-7% -$15.4M 1.5% 6
2016
Q2 		$227M Buy
272,656
+55,247
+25% +$46.1M 1.59% 4
2016
Q1 		$200M Buy
217,409
+3,222
+2% +$3.08M 1.33% 6
2015
Q4 		$221M Sell
214,187
-11,021
-5% -$11.1M 1.4% 6
2015
Q3 		$212M Buy
225,208
+936
+0.4% +$976K 1.46% 5
2015
Q2 		$234M Buy
+224,272
New +$235M 1.44% 6

Other funds holding AGN.PRA

PWS
Peloton Wealth Strategists Indianapolis, Indiana $271M AUM 19.14% 1-Year Est. Return

Calamos Advisors's AGN.PRA Position: Q1 2018 in Review

Calamos Advisors sold out of Allergan plc (AGN.PRA) in Q1 2018, closing a stake of 157,766 shares — an estimated $92.5M sold.

Calamos Advisors first reported a position in AGN.PRA in Q2 2015 and held it in 11 quarters. The position peaked at $234M in Q2 2015. 1 fund tracked by Wall St. Rank holds AGN.PRA as of Q1 2018.

  • Calamos Advisors reported no remaining Allergan plc position as of Q1 2018 after selling out during the quarter.
  • Calamos Advisors sold 157,766 Allergan plc shares in Q1 2018, an estimated $92.5M.
  • Calamos Advisors first reported a position in Allergan plc in Q2 2015 and held it in 11 quarters.
  • Calamos Advisors's Allergan plc position peaked at $234M in Q2 2015.
  • 1 fund tracked by Wall St. Rank held Allergan plc as of Q1 2018.

Based on Calamos Advisors's 13F filing for Q1 2018, filed 13 Apr 2018.